PCI Pharma Services Capabilities Update October 2026: Fill FInish

Bringing an injectable drug product from development through commercialization requires more than fill-finish capacity. It requires a manufacturing strategy that can scale, adapt to multiple formats and connect seamlessly with downstream assembly and packaging.

PCI’s global sterile manufacturing network supports biologics, monoclonal antibodies, peptides, proteins and other modalities across clinical and commercial stages. Capabilities span formulation and lyophilization cycle development, analytical testing, sterile filling of vials, pre-filled syringes and cartridges, and complex injectable formulations. Continued investment is also expanding high-speed filling, automated visual inspection and drug-device combination capabilities across North America and Europe.

With scalable batch sizes, integrated packaging and device assembly, and regulatory experience across global markets, PCI provides a connected approach designed to simplify technology transfer and strengthen supply chain resilience. Explore the presentation to learn how these capabilities can support injectable products throughout their lifecycle.